CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops precision immunoregulatory medicines based on tissue Treg biology
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...